Research programme: therapeutic monoclonal antibodies - Apexigen/Janssen Biotech

Drug Profile

Research programme: therapeutic monoclonal antibodies - Apexigen/Janssen Biotech

Latest Information Update: 20 Mar 2014

Price : $50

At a glance

  • Originator Apexigen; Centocor Ortho Biotech
  • Developer Apexigen; Janssen Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 20 Mar 2014 Early research is ongoing in USA
  • 22 Jun 2011 Centocor Ortho Biotech is now called Janssen Biotech
  • 07 Dec 2010 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top